المؤلفون: El'vira Ivanovna Beloborodova, Evgeniya Georgievna Lambrova, Ekaterina Vital'evna Beloborodova, Valentina Leonidovna Ostanko, Anna Stepanovna Alekseeva, Tat'yana Petrovna Kalacheva, Inna Kliment'evna Livshits, Dina Vladimirovna Chvyrina, E I Beloborodova, E G Lambrova, E V Beloborodova, V L Ostanko, A S Alekseyeva, T P Kalacheva, D V Chvyrina

المصدر: Терапевтический архив, Vol 82, Iss 11, Pp 41-45 (2010)

مصطلحات موضوعية: viral hepatitis, quality of life, viremia duration, Medicine

وصف الملف: electronic resource

Relation: https://ter-arkhiv.ru/0040-3660/article/view/30731; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342

URL الوصول: https://doaj.org/article/70c23497383c4381be72a9fd8743f513

المؤلفون: E V Beloborodova, El'vira Ivanovna Beloborodova, O E Akbasheva, V Yu Serebrov, G E Chernogoryuk, M I Rachkovskiy, I L Purlik, V L Ostanko, D V Chvyrina, E I Beloborodova, M I Rachkovsky

المصدر: Терапевтический архив, Vol 82, Iss 2, Pp 29-34 (2010)

مصطلحات موضوعية: chronic viral hepatitis, alcoholic liver damage, drug addiction, elastase-like and collagenase-like proteinases, α1-proteinase inhibitor, α2-macroglobulin, hydroxyproline, fibronectin, Medicine

وصف الملف: electronic resource

Relation: https://ter-arkhiv.ru/0040-3660/article/view/30539; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342

URL الوصول: https://doaj.org/article/291aed7e5d574e7cad9bd5d2782063c1

المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, I. K. Livshits, V. L. Ostanko, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, Yu. V. Gorelova, В. В. Калюжин, А. Т. Тепляков, И. Д. Беспалова, Е. В. Калюжина, Н. Н. Терентьева, И. К. Лившиц, В. Л. Останко, Е. В. Гракова, К. В. Копьева, В. Ю. Усов, Н. П. Гарганеева, Ю. В. Горелова

المصدر: Bulletin of Siberian Medicine; Том 21, № 2 (2022); 152-167 ; Бюллетень сибирской медицины; Том 21, № 2 (2022); 152-167 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2022-21-2

مصطلحات موضوعية: ультрафильтрация, diuretic resistance, terminology, mechanisms, water and salt restriction, sequential nephron blockade, gliflozines, vaptans, inotropes, vasoconstrictors, glucocorticoids, serelaxin, nesiritide, albumin, ultrafiltration, резистентность к диуретикам, терминология, механизмы, водно-солевой режим, секвенциальная блокада нефрона, глифлозины, ваптаны, инотропы, вазоконстрикторы, глюкокортикостероиды, серелаксин, несиритид, альбумин

وصف الملف: application/pdf

Relation: https://bulletin.tomsk.ru/jour/article/view/4826/3214; Калюжин В.В., Тепляков А.Т., Калюжин О.В. Сердечная недостаточность. М.: Медицинское информационное агентство, 2018:376.; Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 2016;18(8):891−975. DOI:10.1002/ejhf.592.; Moradi M., Daneshi F., Behzadmehr R., Rafiemanesh H., Bouya S., Raeisi M. Quality of life of chronic heart failure patients: a systematic review and meta-analysis. Heart Fail. Rev. 2020;25:993–1006. DOI:10.1007/s10741-019-09890-2.; Comín-Colet J., Martín Lorenzo T., González-Domínguez A., Oliva J., Jiménez Merino S. Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review. Health Qual Life Outcomes. 2020;18:329. DOI:10.1186/s12955-020-01566-y.; Калюжин В.В., Тепляков А.Т., Рязанцева Н.В., Беспалова И.Д., Камаев Д.Ю., Калюжина Е.В. Качество жизни больных ишемической болезнью сердца, ассоциированной с метаболическим синдромом: результаты факторного анализа. Терапевтический архив. 2012;84(12):18−22.; Goudot F.X., Thomas S., Foureur N. Patient âgé insuffisant cardiaque, qualité ou quantité de vie? Soins Gerontol. 2020;25(144):38−42. DOI:10.1016/j.sger.2020.06.009.; Калюжин В.В., Тепляков А.Т., Беспалова И.Д., Калюжина Е.В., Терентьева Н.Н., Сибирева О.Ф. и др. Прогрессирующая (advanced) сердечная недостаточность. Бюллетень сибирской медицины. 2021;20(1):129–146. DOI:10.20538/1682-0363-2021-1-129-146.; Koshy A.O., Gallivan E.R., McGinlay M., Straw S., Drozd M., Toms A.G. et al. Prioritizing symptom management in the treatment of chronic heart failure. ESC Heart Fail. 2020;7(5) 2193–2207. DOI:10.1002/ehf2.12875.; Mullens W., Damman K., Harjola V.P., Mebazaa A., BrunnerLa Rocca H.P., Martens P. et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019;21(2):137–155. DOI:10.1002/ejhf.1369.; Boorsma E.M., Ter Maaten J.M., Damman K., Dinh W., Gustafsson F., Goldsmith S. et al. Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat. Rev. Cardiol. 2020;17(10):641−655. DOI:10.1038/s41569-020-0379-7.; Simonavičius J., Knackstedt C., Brunner-La Rocca H.P. Loop diuretics in chronic heart failure: how to manage congestion? Heart Fail Rev. 2019;24(1):17–30. DOI:10.1007/s10741-018-9735-7.; Jardim S.I., Ramos Dos Santos L., Araújo I., Marques F., Branco P., Gaspar A., Fonseca C. A 2018 overview of diuretic resistance in heart failure. Rev. Port. Cardiol. 2018;37(11):935−945. DOI:10.1016/j.repc.2018.03.014.; Бердибеков Б.Ш. Диуретическая терапия при сердечной недостаточности: фокус на резистентность к диуретикам. Креативная кардиология. 2018;12(4):366–382. DOI:10.24022/1997-3187-2018-12-4-366-382.; Felker G.M., Ellison D.H., Mullens W., Cox Z.L., Testani J.M. Diuretic therapy for patients with heart failure: JACC state-ofthe-art review. J. Am. Coll. Cardiol. 2020;75(10):1178–1195. DOI:10.1016/j.jacc.2019.12.059.; Мареев В.Ю., Гарганеева А.А., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н. и др. Экспертное мнение по применению диуретиков при хронической сердечной недостаточности. Общество специалистов по сердечной недостаточности. Кардиология. 2020;60(12):13−47. DOI:10.18087/cardio.2020.12.n1427.; Reed B.N., Devabhakthuni S. Diuretic resistance in acute decompensated heart failure: a challenging clinical conundrum. Crit. Care Nurs. Q. 2017;40(4):363–373. DOI:10.1097/CNQ.0000000000000173.; Palazzuoli A., Ruocco G., Paolillo S., Perrone Filardi P. The use of diuretics in heart failure with congestion: we can’t judge a book by its cover. ESC Heart Fail. 2019;6(6):1222–1225. DOI:10.1002/ehf2.12515.; Kazory A., Costanzo M.R. The never-ending quest for the appropriate role of ultrafiltration. Eur. J. Heart Fail. 2019;21(7):949. DOI:10.1002/ejhf.1490.; Фомин В.В., Хамхоева М.С. Резистентность к диуретикам: причины, механизмы, возможности преодоления. Фарматека. 2010;12:19–23.; Cox Z.L., Testani J.M. Loop diuretic resistance complicating acute heart failure. Heart Fail. Rev. 2020;25(1):133–145. DOI:10.1007/s10741-019-09851-9.; Suri S.S., Pamboukian S.V. Optimal diuretic strategies in heart failure. Ann. Transl. Med. 2021;9(6):517. DOI:10.21037/atm20-4600.; Дядык А.И., Куглер Т.Е., Щукина Е.В., Ракитская И.В., Зборовский С.Р., Сулиман Ю.В. Диуретическая резистентность: механизмы, лечебная тактика и профилактика. Фарматека. 2017;18:50−56.; Testani J.M., Brisco M.A., Turner J.M., Spatz E.S., Bellumkonda L., Parikh C.R. et al. Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ. Heart Fail. 2014;7(2):261–270. DOI:10.1161/CIRCHEARTFAILURE.113.000895.; Epstein M., Lepp B.A., Hoffman D.S., Levinson R. Potentiation of furosemide by metolazone in refractory edema. Curr. Ther. Res. 1977;21:656–667.; Kumar D., Bagarhatta R. Fractional excretion of sodium and its association with prognosis of decompensated heart failure patients. J. Clin. Diagn. Res. 2015;9(4):OC01–OC03. DOI:10.7860/JCDR/2015/11532.5736.; Testani J.M., Hanberg J.S., Cheng S., Rao V., Onyebeke C., Laur O. et al. Rapid and highly accurate prediction of poor loop diuretic natriuretic response in patients with heart failure. Circ. Heart Fail. 2016;9(1):e002370. DOI:10.1161/CIRCHEARTFAILURE.115.002370.; Doering A., Jenkins C.A., Storrow A.B., Lindenfeld J., Fermann G.J., Miller K.F. et al. Markers of diuretic resistance in emergency department patients with acute heart failure. Int. J. Emerg. Med. 2017;10(1):17. DOI:10.1186/s12245-017-0143-x.; Ter Maaten J.M., Dunning A.M., Valente M.A., Damman K., Ezekowitz J.A., Califf R.M. et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am. Heart J. 2015;170(2):313–321. DOI:10.1016/j.ahj.2015.05.003.; Cox Z.L., Sarrell B.A., Cella M.K., Tucker B., Arroyo J.P., Umanath K. et al. Multinephron segment diuretic therapy to overcome diuretic resistance in acute heart failure: a single-center experience. J. Card. Fail. 2021:S1071-9164(21)00333-X. DOI:10.1016/j.cardfail.2021.07.016.; Ter Maaten J.M., Valente M.A., Damman K., Cleland J.G., Givertz M.M., Metra M. et al. Combining diuretic response and hemoconcentration to predict rehospitalization after admission for acute heart failure. Circ. Heart Fail. 2016;9(6):e002845. DOI:10.1161/CIRCHEARTFAILURE.115.002845.; Neuberg G.W., Miller A.B., O’Connor C.M., Belkin R.N., Carson P.E., Cropp A.B. et al. PRAISE Investigators. Prospective randomized amlodipine survival evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J. 2002;44(1):31–38. DOI:10.1067/mhj.2002.123144.; Trullàs J.C., Casado J., Morales-Rull J.L., Formiga F., Conde-Martel A., Quirós R. et al. Prevalence and outcome of diuretic resistance in heart failure. Intern. Emerg. Med. 2019;14(4):529−537. DOI:10.1007/s11739-018-02019-7.; Côté J.M., Bouchard J., Murray P.T., Beaubien-Souligny W. Diuretic strategies in patients with resistance to loop-diuretics in the intensive care unit: A retrospective study from the MIMIC-III database. J. Crit. Care. 2021;65:282–291. DOI:10.1016/j.jcrc.2021.06.009.; Bellomo R., Prowle J.R., Echeverri J.E. Diuretic therapy in fluid-overloaded and heart failure patients. Contrib. Nephrol. 2010;164:153–163. DOI:10.1159/000313728.; Katz S.D. In search of euvolemia in heart failure. JACC Heart Fail. 2014;2(3):306–307. DOI:10.1016/j.jchf.2014.02.006.; Cox Z.L., Testani J.M. Loop diuretic resistance in a patient with acute heart failure. In: Tamg W.H.W., Verbrugge F.H., Mullens W., eds. Cardiorenal syndrome in heart failure. London, UK: Springer Nature, 2019:153–173.; Elhassan M.G., Chao P.W., Curiel A. The conundrum of volume status assessment: revisiting current and future tools available for physicians at the bedside. Cureus. 2021;13(5):e15253. DOI:10.7759/cureus.15253.; Watson K., Gottlieb S.S. Walking the line of euvolemia. J. Card. Fail. 2014;20(8):623−624. DOI:10.1016/j.cardfail.2014.06.356.; Sokolska J.M., Sokolski M., Zymliński R., Biegus J., Siwołowski P., Nawrocka-Millward S. et al. Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. ESC Heart Fail. 2020;7(6):3830–3840. DOI:10.1002/ehf2.12973.; Verbrugge F.H. Editor’s choice-diuretic resistance in acute heart failure. Eur. Heart J. Acute Cardiovasc. Care. 2018;7(4):379-389. DOI:10.1177/2048872618768488.; Gupta R., Testani J., Collins S. Diuretic resistance in heart failure. Curr. Heart Fail. Rep. 2019;16(2):57−66. DOI:10.1007/s11897-019-0424-1.; Yang Y.J., Kim J., Kwock C.K. Association of genetic variation in the epithelial sodium channel gene with urinary sodium excretion and blood pressure. Nutrients. 2018;10(5):612. DOI:10.3390/nu10050612.; Kenig A., Kolben Y., Asleh R., Amir O., Ilan Y. Improving diuretic response in heart failure by implementing a patient-tailored variability and chronotherapy-guided algorithm. Front Cardiovasc. Med. 2021;8:695547. DOI:10.3389/fcvm.2021.695547.; Ellison D.H., Felker G.M. Diuretic treatment in heart failure. N. Engl. J. Med. 2017;377(20):1964–1975. DOI:10.1056/NEJMra1703100.; Hoorn E.J., Wilcox C.S., Ellison D.H. Chapter 50. Diuretics. Brenner and Rector’s the kidney eleventh edition. Elsevier, Philadelphia, PA; 2020:1708–1740.; Wilcox C.S., Testani J.M., Pitt B. Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension. 2020;76(4):1045–1054. DOI:10.1161/HYPERTENSIONAHA.120.15205.; Ravera A., Ter Maaten J.M., Metra M. Diuretic resistance and chronic heart failure. In: Tamg W.H.W., Verbrugge F.H., Mullens W., eds. Cardiorenal syndrome in heart failure. London, UK: Springer Nature, 2019:121–135. DOI:10.1007/978-3-030-21033-5_9.; Rao V.S., Planavsky N., Hanberg J.S., Ahmad T., BriscoBacik M.A., Wilson F.P. et al. Compensatory distal reabsorption drives diuretic resistance in human heart failure. J. Am. Soc. Nephrol. 2017;28(11):3414–3424. DOI:10.1681/ASN.2016111178.; Калюжин В.В., Тепляков А.Т., Черногорюк Г.Э., Калюжина Е.В., Беспалова И.Д., Терентьева Н.Н. и др. Хроническая сердечная недостаточность: синдром или заболевание? Бюллетень сибирской медицины. 2020;19(1):134–139. DOI:10.20538/1682-0363-2020-1-134–139.; Ройтберг Г.Е., Струтынский А.В. Внутренние болезни. Сердечно-сосудистая система: учеб. пособие. М.: МЕДпресс-информ, 2019:904.; McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2021;42(36):3599– 3726. DOI:10.1093/eurheartj/ehab670.; Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H. et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62(16):e147–239. DOI:10.1016/j.jacc.2013.05.019.; Lennie T.A., Song E.K., Wu J.R., Chung M.L., Dunbar S.B., Pressler S.J., Moser D.K. Three-gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure. J. Card. Fail. 2011;17(4):325–330. DOI:10.1016/j.cardfail.2010.11.008.; Billingsley H.E., Hummel S.L., Carbone S. The role of diet and nutrition in heart failure: A state-of-the-art narrative review. Prog. Cardiovasc. Dis. 2020;63(5):538−551. DOI:10.1016/j.pcad.2020.08.004.; Burgermaster M., Rudel R., Seres D. Dietary sodium restriction for heart failure: a systematic review of intervention outcomes and behavioral determinants. Am. J. Med. 2020;133(12):1391- 1402. DOI:10.1016/j.amjmed.2020.06.018.; Doukky R., Avery E., Mangla A., Collado F.M., Ibrahim Z., Poulin M.F. et al. Impact of dietary sodium restriction on heart failure outcomes. JACC Heart Fail. 2016;4(1):24–35. DOI:10.1016/j.jchf.2015.08.007.; Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Беграмбекова Ю.Л., Васюк Ю.А., Гарганеева А.А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(S6):8−161. DOI:10.18087/cardio.2475.; Patel Y., Joseph J. Sodium Intake and Heart Failure. Int. J. Mol. Sci. 2020;21(24):9474. DOI:10.3390/ijms21249474.; Международное руководство по сердечной недостаточности; ред. С.Дж. Болл, Р.В.Ф. Кемпбелл, Г.С. Френсис; пер. с англ. М.: Медиа Сфера, 1995:89.; Metra M., Ponikowski P., Dickstein K., McMurray J.J., Gavazzi A., Bergh C.H. et al. .Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2007;9(6–7):684−694. DOI:10.1016/j.ejheart.2007.04.003.; Bhatt A.S., Yanamandala M., Konstam M.A. For vaptans, as for life, balance is better. Eur. J. Heart Fail. 2021;23(5):751−753. DOI:10.1002/ejhf.2042.; Rodriguez M., Hernandez M., Cheungpasitporn W., Kashani K.B., Riaz I., Rangaswami J. et al. Hyponatremia in heart failure: pathogenesis and management. Curr. Cardiol. Rev. 2019;15(4):252–261. DOI:10.2174/1573403X15666190306111812.; Gunderson E.G., Lillyblad M.P., Fine M., Vardeny O., Berei T.J. Tolvaptan for volume management in heart failure. Pharmacotherapy. 2019;39(4):473−485. DOI:10.1002/phar.2239.; Yetkin E., Cuglan B., Turhan H., Ozturk S. A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics. Cardiovasc. Endocrinol. Metab. 2020;9(2):60−63. DOI:10.1097/XCE.0000000000000200.; Buckley L.F., Carter D.M., Matta L., Cheng J.W., Stevens C., Belenkiy R.M. et al. Intravenous diuretic therapy for the management of heart failure and volume overload in a multidisciplinary outpatient unit. JACC Heart Fail. 2016;4(1):1−8. DOI:10.1016/j.jchf.2015.06.017.; Halatchev I.G., Wu W.C., Heidenreich P.A., Djukic E., Balasubramanian S., Ohlms K.B. et al. Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. Int. J. Cardiol. Heart Vasc. 2021;36:100860. DOI:10.1016/j.ijcha.2021.100860.; Verma V., Zhang M., Bell M., Tarolli K., Donalson E., Vaughn J. et al. Outpatient intravenous diuretic clinic: an effective strategy for management of volume overload and reducing immediate hospital admissions. J. Clin. Med. Res. 2021;13(4):245–251. DOI:10.14740/jocmr4499.; Buggey J., Mentz R.J., Pitt B., Eisenstein E.L., Anstrom K.J., Velazquez E.J. et al. A reappraisal of loop diuretic choice in heart failure patients. Am. Heart J. 2015;169(3):323–333. DOI:10.1016/j.ahj.2014.12.009.; Balsam P., Ozierański K., Marchel M., Gawałko M., Niedziela Ł., Tymińska A. et al. Comparative effectiveness of torasemide versus furosemide in symptomatic therapy in heart failure patients: Preliminary results from the randomized TORNADO trial. Cardiol. J. 2019;26(6):661−668. DOI:10.5603/CJ.a2019.0114.; Ozierański K., Balsam P., Kapłon-Cieślicka A., Tymińska A., Kowalik R., Grabowski M. et al. Comparative analysis of longterm outcomes of torasemide and furosemide in heart failure patients in heart failure registries of the European Society of Cardiology. Cardiovasc. Drugs Ther. 2019;33(1):77−86. DOI:10.1007/s10557-018-6843-5.; Verbrugge F.H., Martens P., Ameloot K., Haemels V., Penders J., Dupont M. et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. Eur. J. Heart Fail. 2019;21(11):1415–1422. DOI:10.1002/ejhf.1478.; Gill D., Gadela N.V., Azmeen A., Jaiswal A. Usefulness of acetazolamide in the management of diuretic resistance. Proc. (Bayl. Univ. Med. Cent.). 2020;34(1):169–171. DOI:10.1080/08998280.2020.1830332.; Testani J.M., Chen J., McCauley B.D., Kimmel S.E., Shannon R.P. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–272. DOI:10.1161/CIRCULATIONAHA.109.933275.; Brisco M.A., Zile M.R., Hanberg J.S., Wilson F.P., Parikh C.R., Coca S.G. et al. Relevance of changes in serum creatinine during a heart failure trial of decongestive strategies: insights from the DOSE trial. J. Card. Fail. 2016;22:753–760. DOI:10.1016/j.cardfail.2016.06.423.; Gheorghiade M., Vaduganathan M., Ambrosy A., Böhm M., Campia U., Cleland J.G. et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail. Rev. 2013;18(2):107–122. DOI:10.1007/s10741-012-9315-1.; Peri-Okonny P.A., Mi X., Khariton Y., Patel K.K., Thomas L., Fonarow G.C. et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7(4):350–358. DOI:10.1016/j.jchf.2018.11.011.; Martín-Pérez M., Michel A., Ma M., García Rodríguez L.A. Development of hypotension in patients newly diagnosed with heart failure in UK general practice: retrospective cohort and nested case-control analyses. BMJ Open. 2019;9(7):e028750. DOI:10.1136/bmjopen-2018-028750.; Cautela J., Tartiere J.M., Cohen-Solal A., Bellemain-Appaix A., Theron A., Tibi T. et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur. J. Heart Fail. 2020;22(8):1357–1365. DOI:10.1002/ejhf.1835.; Crespo-Leiro M.G., Metra M., Lund L.H., Milicic D., Costanzo M.R., Filippatos G. et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2018;20(11):1505−1535. DOI:10.1002/ejhf.1236.; Tariq S., Aronow W.S. Use of inotropic agents in treatment of systolic heart failure. Int. J. Mol. Sci. 2015;16(12):29060– 29068. DOI:10.3390/ijms161226147.; Patel P.H., Nguyen M., Rodriguez R., Surani S., Udeani G. Omecamtiv mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management. Cureus. 2021;13(1):e12419. DOI:10.7759/cureus.12419.; Xiangli S., Lan L., Libiya Z., Jun M., Shubin J. Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance. Libyan J. Med. 2021;16(1):1973762. DOI:10.1080/19932820.2021.1973762.; Heringlake M., Alvarez J., Bettex D., Bouchez S., Fruhwald S., Girardis M. et al. An update on levosimendan in acute cardiac care: applications and recommendations for optimal efficacy and safety. Expert Rev. Cardiovasc. Ther. 2021;19(4):325– 335. DOI:10.1080/14779072.2021.1905520.; Asai Y., Sato T., Kito D., Yamamoto T., Hioki I., Urata Y. et al. Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist’s proposal: a case report. J. Pharm. Health Care Sci. 2021;7(1):10. DOI:10.1186/s40780-021-00193-z.; Li S., Zhao Q., Zhen Y., Li L., Mi Y., Li T. et al. The Impact of Glucocorticoid Therapy on Guideline-Directed Medical Treatment Titration in Patients Hospitalized for Heart Failure with Low Blood Pressure: A Retrospective Study. Int. J. Gen. Med. 2021;14:6693–6701. DOI:10.2147/IJGM.S334132.; Liu C., Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. J. Card. Fail. 2014;20(9):625−629. DOI:10.1016/j.cardfail.2014.06.353.; Liu C., Ge N., Zhai J.L., Zhang J.X. Dexamethasone-induced diuresis is associated with inhibition of the renin-angiotensin-aldosterone system in rats. Kaohsiung J. Med. Sci. 2016;32(12):614−619. DOI:10.1016/j.kjms.2016.09.007.; Smets P.M., Lefebvre H.P., Aresu L., Croubels S., Haers H., Piron K. et al. Renal function and morphology in aged Beagle dogs before and after hydrocortisone administration. PLoS One. 2012;7(2):e31702. DOI:10.1371/journal.pone.0031702.; Batool A., Salehi N., Chaudhry S., Cross M., Malkawi A., Siraj A. Role of vasodilator therapy in acute heart failure. Cureus. 2021;13(8):e17126. DOI:10.7759/cureus.17126.; Cox Z.L., Hung R., Lenihan D.J., Testani J.M. Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail. 2020;8(3):157−168. DOI:10.1016/j.jchf.2019.09.012.; Ng T.M., Goland S., Elkayam U. Relaxin for the treatment of acute decompensated heart failure: pharmacology, mechanisms of action, and clinical evidence. Cardiol. Rev. 2016;24(4):194–204. DOI:10.1097/CRD.0000000000000089.; Bani D. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target. Drug Discov. Today. 2020;25(7):1239–1244. DOI:10.1016/j.drudis.2020.04.014.; Caprnda M., Zulli A., Shiwani H.A., Kubatka P., Filipova S., Valentova V. et al. The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure. Clin. Exp. Pharmacol. Physiol. 2020;47(7):1120–1133. DOI:10.1111/1440-1681.13290.; Wang L., Zhang Q., Liu M., Chen S., Han S., Li J. et al. Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis. J. Int. Med. Res. 2019;47(11):5414−5425. DOI:10.1177/0300060519882221.; Urbach J., Goldsmith S.R. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials. Ther. Adv. Cardiovasc. Dis. 2021;15:175394472097 7741. DOI:10.1177/1753944720977741.; Welch W.J. Adenosine type 1 receptor antagonists in fluid retaining disorders. Expert. Opin. Investig. Drugs. 2002;11(11):1553–1562. DOI:10.1517/13543784.11.11.1553.; Jhund P.S., Solomon S.D., Docherty K.F., Heerspink H.J.L., Anand I.S., Böhm M. et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation. 2021;143(4):298–309. DOI:10.1161/CIRCULATIONAHA.120.050391.; Griffin M., Rao V.S., Ivey-Miranda J., Fleming J., Mahoney D., Maulion C. et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;142(11):1028–1039. DOI:10.1161/CIRCULATIONAHA.120.045691.; Sarzani R., Giulietti F., Di Pentima C., Spannella F. Sodium-glucose co-transporter-2 inhibitors: peculiar «hybrid» diuretics that protect from target organ damage and cardiovascular events. Nutr. Metab. Cardiovasc. Dis. 2020;30(10):1622– 1632. DOI:10.1016/j.numecd.2020.05.030.; Delanaye P., Scheen A.J. The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection. Diabetes Metab. 2021;47(6):101285. DOI:10.1016/j.diabet.2021.101285.; Lee T.H., Kuo G., Chang C.H., Huang Y.T., Yen C.L., Lee C.C. et al. Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: an updated systematic review and meta-analysis. PLoS One. 2021;16(12):e0260312. DOI:10.1371/journal.pone.0260312.; Kitsios G.D., Mascari P., Ettunsi R., Gray A.W. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J. Crit. Care. 2014;29(2):253–259. DOI:10.1016/j.jcrc.2013.10.004.; Mahmoodpoor A., Zahedi S., Pourakbar A., Hamishehkar H., Shadvar K., Asgharian P. et al. Efficacy of furosemide-albumin compared with furosemide in critically ill hypoalbuminemia patients admitted to intensive care unit: a prospective randomized clinical trial. Daru. 2020;28(1):263–269. DOI:10.1007/s40199-020-00339-8.; Urban S., Błaziak M., Biegus J., Zymliński R. Ultrafiltration in acute heart failure: current knowledge and fields for further research. Adv. Clin. Exp. Med. 2021;30(7):737−746. DOI:10.17219/acem/135347.; Prins K.W., Wille K.M., Tallaj J.A., Tolwani A.J. Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1. Clin. Kidney J. 2015;8(1):87−92. DOI:10.1093/ckj/sfu123.; Shi X., Bao J., Zhang H., Wang H., Li L., Zhang Y. Patients with high-dose diuretics should get ultrafiltration in the management of decompensated heart failure: a meta-analysis. Heart Fail. Rev. 2019;24(6):927−940. DOI:10.1007/s10741-019-09812-2.; Morales R.O., Barbosa F., Farre N. Peritoneal dialysis in heart failure: focus on kidney and ventricular dysfunction. Rev. Cardiovasc. Med. 2021;22(3):649−657. DOI:10.31083/j.rcm2203075.; Chionh C.Y., Clementi A., Poh C.B., Finkelstein F.O., Cruz D.N. The use of peritoneal dialysis in heart failure: A systematic review. Perit. Dial. Int. 2020;40(6):527−539. DOI:10.1177/0896860819895198.; Yazdanyar A., Sanon J., Lo K.B., Joshi A.M., Kurtz E., Saqib M.N. et al. Outcomes with ultrafiltration among hospitalized patients with acute heart failure (from the national inpatient sample). Am. J. Cardiol. 2021;142:97–102. DOI:10.1016/j.amjcard.2020.11.041.; Rajapreyar I., Kumar S., Rao R.A. Ambulatory advanced heart failure patients: timing of mechanical circulatory support - delaying the inevitable? Curr. Opin. Cardiol. 2021;36(2):186– 197. DOI:10.1097/HCO.0000000000000831.; Lombardi C.M., Cimino G., Pellicori P., Bonelli A., Inciardi R.M., Pagnesi M. et al. Congestion in patients with advanced heart failure: assessment and treatment. Heart Fail. Clin. 2021;17(4):575–586. DOI:10.1016/j.hfc.2021.05.003.; Antonides C.F.J., Schoenrath F., de By T.M.M.H., Muslem R., Veen K., Yalcin Y.C. et al. EUROMACS investigators. Outcomes of patients after successful left ventricular assist device explantation: a EUROMACS study. ESC Heart Fail. 2020;7(3):1085–1094. DOI:10.1002/ehf2.12629.; Griffin M., Soufer A., Goljo E., Colna M., Rao V.S., Jeon S. et al Real world use of hypertonic saline in refractory acute decompensated heart failure: a U.S. center’s experience. JACC Heart Fail. 2020;8(3):199–208. DOI:10.1016/j.jchf.2019.10.012.; Covic A., Copur S., Tapoi L., Afsar B., Ureche C., Siriopol D. et al. Efficiency of hypertonic saline in the management of decompensated heart failure: a systematic review and meta-analysis of clinical studies. Am. J. Cardiovasc. Drugs. 2021;21(3):331–347. DOI:10.1007/s40256-020-00453-7.; Birch F., Boam E., Parsons S., Ghosh J., Johnson M.J. ‘Subcutaneous furosemide in advanced heart failure: service improvement project’. BMJ Support Palliat. Care. 2021:bmjspcare-2020-002803. DOI:10.1136/bmjspcare-2020-002803.; López-Vilella R., Sánchez-Lázaro I., Husillos Tamarit I., Monte Boquet E., Núñez Villota J., Donoso Trenado V. et al. Administration of subcutaneous furosemide in elastomeric pump vs. oral solution for the treatment of diuretic refractory congestion. High Blood Press. Cardiovasc. Prev. 2021;28(6):589−596. DOI:10.1007/s40292-021-00476-4.; Acar S., Sanli S., Oztosun C., Afsar B., Sag A.A., Kuwabara M. et al. Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. Int. Urol. Nephrol. 2021;53(9):1839–1849. DOI:10.1007/s11255-020-02704-7.; Voors A.A., Kremer D., Geven C., Ter Maaten J.M., Struck J., Bergmann A. et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur. J. Heart Fail. 2019;21(2):163–171. DOI:10.1002/ejhf.1366.; Liu W., Yan J., Pan W., Tang M. Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system. Ann. Transl. Med. 2020;8(5):243. DOI:10.21037/atm.2020.02.07.; Ma Z., Song J.J., Martin S., Yang X.C., Zhong J.C. The Elabela-APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev. 2021;26(5):1249–1258. DOI:10.1007/s10741-020-09957-5.; Fudim M., Ganesh A., Green C., Jones W.S., Blazing M.A., DeVore A.D. et al. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. Eur. Heart J. 2018;39(48):4255−4256. DOI:10.1093/eurheartj/ehy682.; Fudim M., Ponikowski P.P., Burkhoff D., Dunlap M.E., Sobotka P.A., Molinger J. et al. Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. Eur. J. Heart Fail. 2021;23(7):1076–1084. DOI:10.1002/ejhf.2196.; Козловская Н.Л. Низкомолекулярные гепарины в практике нефролога. Клиническая нефрология. 2011;1:15– 22.; Targonski R., Sadowski J., Cyganski P.A. Impact of anticoagulation on the effectiveness of loop diuretics in heart failure with cardiorenal syndrome and venous thromboembolism. Blood Coagul Fibrinolysis. 2014;25(2):180–182. DOI:10.1097/MBC.0000000000000012.; Pugliese N.R., Fabiani I., Conte L., Nesti L., Masi S., Natali A. et al. Persistent congestion, renal dysfunction and inflammatory cytokines in acute heart failure: a prognosis study. J. Cardiovasc. Med. (Hagerstown). 2020;21(7):494−502. DOI:10.2459/JCM.0000000000000974.; Fu K., Hu Y., Zhang H., Wang C., Lin Z., Lu H. et al. Insights of worsening renal function in type 1 cardiorenal syndrome: from the pathogenesis, biomarkers to treatment. Front. Cardiovasc. Med. 2021;8:760152. DOI:10.3389/fcvm.2021.760152.; Тепляков А.Т., Болотская Л.А., Степачева Т.А., Карман Н.В., Рыбальченко Е.В., Шилов С.Н. и др. Супрессивное влияние рекомбинантного иммуномодулятора ронколейкина на уровень провоспалительных цитокинов, аутоантител к кардиолипину в крови и сердечную недостаточность. Кардиология. 2008;48(8):34−40.; Reina-Couto M., Pereira-Terra P., Quelhas-Santos J., Silva-Pereira C., Albino-Teixeira A., Sousa T. Inflammation in human heart failure: major mediators and therapeutic targets. Front Physiol. 2021;12:746494. DOI:10.3389/fphys.2021.746494.; https://bulletin.tomsk.ru/jour/article/view/4826

الاتاحة: https://bulletin.tomsk.ru/jour/article/view/4826
https://doi.org/10.20538/1682-0363-2022-2-152-167

المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, G. E. Chernogoryuk, E. V. Kalyuzhina, I. D. Bespalova, N. N. Terentyeva, I. K. Livshits, V. L. Ostanko, O. F. Sibireva, N. Yu. Chasovskikh

المصدر: Бюллетень сибирской медицины, Vol 19, Iss 1, Pp 134-139 (2020)

مصطلحات موضوعية: хроническая сердечная недостаточность, дефиниция, международная статистическая классификация болезней и проблем, связанных со здоровьем, синдром, болезнь, правила формулировки диагноза, Medicine

Relation: https://bulletin.ssmu.ru/jour/article/view/2693; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/10f8e52a76df47aba8f729623ae7d0db

الاتاحة: https://doi.org/10.20538/1682-0363-2020-1-134-139
https://doaj.org/article/10f8e52a76df47aba8f729623ae7d0db

المؤلفون: V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, V. L. Ostanko, N. N. Terentyeva, I. K. Livshits, A. A. Shalovay, O. F. Sibireva, M. A. Solovtsov

المصدر: Бюллетень сибирской медицины, Vol 19, Iss 3, Pp 128-136 (2020)

مصطلحات موضوعية: хроническая сердечная недостаточность, классификация, стадия, функциональный класс, левый желудочек, фракция выброса, диастолическая функция, хроническое легочное сердце, тест 6-минутной ходьбы, диагностическое заключение, Medicine

Relation: https://bulletin.ssmu.ru/jour/article/view/2997; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/2ab39b9064bb4a1d8b25f1c3e59e7a57

الاتاحة: https://doi.org/10.20538/1682-0363-2020-3-128-136
https://doaj.org/article/2ab39b9064bb4a1d8b25f1c3e59e7a57

المؤلفون: T. P. Kalacheva, G. M. Chernyavskaya, T. S. Ageeva, I. K. Livshits, V. L. Ostanko, E. V. Bolotova, O. A. Denisova, M. V. Listopadova

المصدر: Бюллетень сибирской медицины, Vol 17, Iss 4, Pp 229-237 (2018)

مصطلحات موضوعية: цирроз печени, легочная артериальная гипертензия, легочно-сердечная гемодинамика, саркоидоз органов дыхания, Medicine

Relation: https://bulletin.ssmu.ru/jour/article/view/1996; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/5ba31d7a38f0441ab340b95afe31ff7f

الاتاحة: https://doi.org/10.20538/1682-0363-2018-4-229-237
https://doaj.org/article/5ba31d7a38f0441ab340b95afe31ff7f

المؤلفون: V. L. Ostanko, T. P. Kalacheva, E. V. Kalyuzhina, I. K. Livshits, A. A. Shalovay, G. E. Chernogoryuk, I. D. Bespalova, R. Sh. Yunusov, L. V. Lukashova, A. P. Pomogaeva, A. T. Teplyakov, V. V. Kalyuzhin

المصدر: Бюллетень сибирской медицины, Vol 17, Iss 4, Pp 264-280 (2018)

مصطلحات موضوعية: биомаркер, ишемия миокарда, повреждение миокарда, сердечная недостаточность, миокардиальный стресс, атеросклероз, тромбоз, воспаление, матриксное и клеточное ремоделирование, оксидативный стресс, нейрогормоны, кардиоренальный синдром, Medicine

Relation: https://bulletin.ssmu.ru/jour/article/view/1999; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684; https://doaj.org/article/8b89cd9651e4449696e275a39d23099a

الاتاحة: https://doi.org/10.20538/1682-0363-2018-4-264-280
https://doaj.org/article/8b89cd9651e4449696e275a39d23099a

المؤلفون: Yu. A. Strezh, I. A. Koynova, V L Ostanko, Ev. Beloborodova, E. G. Gruzdeva, V. A. Burkovskaya, G. M. Chernyavskaya, G. E. Chernogoryuk

المصدر: Practical medicine. 18:75-81

مصطلحات موضوعية: medicine.medical_specialty, business.industry, medicine, Clinical course, medicine.disease, Intensive care medicine, business, Inflammatory bowel disease, Connection (mathematics)

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5a0f81c6fca25f0b15b463a64034ccd7
https://doi.org/10.32000/2072-1757-2020-4-75-81

المؤلفون: E I, Beloborodova, E G, Lambrova, E V, Beloborodova, V L, Ostanko, A S, Alekseeva, T P, Kalacheva, I K, Livshits, D V, Chvyrina

المصدر: Terapevticheskii arkhiv. 82(11)

مصطلحات موضوعية: Adult, Male, Depressive Disorder, Psychological Tests, Emotions, Hepatitis C, Chronic, Severity of Illness Index, Hypochondriasis, Hepatitis B, Chronic, Social Isolation, Surveys and Questionnaires, Quality of Life, Humans, Female

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::adc0b6c5a0b5358aadbb40edc6e5e60b
https://pubmed.ncbi.nlm.nih.gov/21381348

المؤلفون: E I, Beloborodova, E G, Lambrova, E V, Beloborodova, V L, Ostanko, A S, Alekseeva, T P, Kalacheva, I K, Livshits

المصدر: Klinicheskaia meditsina. 88(5)

مصطلحات موضوعية: Hepatitis, Viral, Human, MMPI, Humans, Psychophysiologic Disorders, Hepatitis, Chronic

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::dac7824e88556f7a02b426a4b01a833f
https://pubmed.ncbi.nlm.nih.gov/21089457

المؤلفون: E I, Beloborodova, R F, Abdrashitov, E V, Beloborodova, V A, Burkovskaia, O E, Akbashaeva, L I, Purlik, M I, Rachkovskiĭ, E G, Lambrova, A S, Alekseeva, L A, Petrova, V L, Ostanko, Iu I, Sinicheva, T P, Kalacheva

المصدر: Klinicheskaia meditsina. 85(9)

مصطلحات موضوعية: Adult, Male, Adolescent, Hepatitis, Viral, Human, Biopsy, Chronic Disease, Disease Progression, Humans, Female, Collagenases, Middle Aged, Prognosis, Biomarkers

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::9ac2a256f24fdcdd7c997fc8f343c284
https://pubmed.ncbi.nlm.nih.gov/18038572

المؤلفون: E I, Beloborodova, A Iu, Aleksandrova, E V, Beloborodova, E Iu, Plotnikova, A S, Alekseeva, E G, Lambrova, L P, Filippova, V L, Ostanko

المصدر: Klinicheskaia meditsina. 84(9)

مصطلحات موضوعية: Adult, Psychological Tests, Depression, Incidence, Chronic Disease, Cholecystitis, Humans, Anxiety, Prognosis, Opisthorchiasis

URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::94c2bc9ce8ff081d4979aeb52c72d02e
https://pubmed.ncbi.nlm.nih.gov/17209447

المؤلفون: E I Beloborodova, G. M. Chernyavskaya, V L Ostanko, Kalacheva Tp, E V Beloborodova, M I Rachkovskiy

المصدر: Scopus-Elsevier

مصطلحات موضوعية: Adult, Liver Cirrhosis, Male, Pulmonary Circulation, medicine.medical_specialty, Cirrhosis, Endothelium, Hypertension, Pulmonary, Hemodynamics, 030204 cardiovascular system & hematology, Doppler echocardiography, Intracardiac injection, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hypertension, Portal, medicine, Humans, 030212 general & internal medicine, Aged, medicine.diagnostic_test, business.industry, Heart, Middle Aged, medicine.disease, Pulmonary hypertension, Echocardiography, Doppler, medicine.anatomical_structure, Ventricle, Cardiology, Portal hypertension, Female, Endothelium, Vascular, Cardiology and Cardiovascular Medicine, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c44950ccc38ceed79afe6649d8cf9ea
http://www.scopus.com/inward/record.url?eid=2-s2.0-84978152795&partnerID=MN8TOARS